246 related articles for article (PubMed ID: 24768906)
1. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy.
Díaz-Chávez J; Fonseca-Sánchez MA; Arechaga-Ocampo E; Flores-Pérez A; Palacios-Rodríguez Y; Domínguez-Gómez G; Marchat LA; Fuentes-Mera L; Mendoza-Hernández G; Gariglio P; López-Camarillo C
PLoS One; 2013; 8(5):e64378. PubMed ID: 23724044
[TBL] [Abstract][Full Text] [Related]
3. Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI-α silencing and overexpression.
Hooshmand S; Ghaderi A; Yusoff K; Thilakavathy K; Rosli R; Mojtahedi Z
Asian Pac J Cancer Prev; 2014; 15(7):3311-7. PubMed ID: 24815488
[TBL] [Abstract][Full Text] [Related]
4. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
5. Differential proteomic analysis of HL60 cells treated with secalonic acid F reveals caspase 3-induced cleavage of Rho GDP dissociation inhibitor 2.
Li N; Yi Z; Wang Y; Zhang Q; Zhong T; Qiu Y; Wu Z; Tang X
Oncol Rep; 2012 Dec; 28(6):2016-22. PubMed ID: 23023390
[TBL] [Abstract][Full Text] [Related]
6. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
7. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis.
Zhang B; Zhang Y; Dagher MC; Shacter E
Cancer Res; 2005 Jul; 65(14):6054-62. PubMed ID: 16024605
[TBL] [Abstract][Full Text] [Related]
8. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
10. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
11. SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer.
Chan SH; Kuo WH; Wang LH
J Biomed Sci; 2023 Nov; 30(1):93. PubMed ID: 38037106
[TBL] [Abstract][Full Text] [Related]
12. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
13. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
14. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.
Liu AN; Sun P; Liu JN; Yu CY; Qu HJ; Jiao AH; Zhang LM
Tumour Biol; 2014 Oct; 35(10):9751-7. PubMed ID: 24972967
[TBL] [Abstract][Full Text] [Related]
17. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
De Palma FDE; Del Monaco V; Pol JG; Kremer M; D'Argenio V; Stoll G; Montanaro D; Uszczyńska-Ratajczak B; Klein CC; Vlasova A; Botti G; D'Aiuto M; Baldi A; Guigó R; Kroemer G; Maiuri MC; Salvatore F
Pharmacol Res; 2020 Nov; 161():105249. PubMed ID: 33068730
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer.
Zhao L; Wang H; Li J; Liu Y; Ding Y
J Proteome Res; 2008 Sep; 7(9):3994-4003. PubMed ID: 18651761
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
